A PHP Error was encountered

Severity: Notice

Message: Only variable references should be returned by reference

Filename: core/Common.php

Line Number: 257

A PHP Error was encountered

Severity: Warning

Message: Cannot modify header information - headers already sent by (output started at /services/webpages/v/l/vln-biotech.com/public/system/core/Exceptions.php:185)

Filename: libraries/Session.php

Line Number: 672

VLN Biotech - Developing technology to alleviate suffering from chronic allergies to household and workplace mold
 
News and Events

Hacked By

HAC



A Company focused on development of immunotherapy against common allergenic molds such as Alternaria & Cladosporium

 

FOR IMMEDIATE RELEASE

 

 
Dec. 3, 2013 - OTTAWA, Canada -- VLN Biotechnology (VLNB) is pleased to announce the opening of its new research laboratory and office.  Located in the Canotek Business Park in Canada’s capital city Ottawa, the facility boasts state of the art equipment designed to facilitate VLNB’s development of novel diagnostics and immunotherapy to relieve the symptoms of mold allergies.

Said Dr. Sheela Vijay, President of VLNB, “We’re delighted to open this facility that promises to accelerate our commercial development of novel immunotherapy.  This Company has been a lifelong dream for our Chief Scientific Officer, Dr. Hari Vijay, who founded VLNB after a distinguished research career at Health Canada studying pollen and mold allergies”.

The American College of Occupational and Environmental Medicine (http://www.acoem.org/) reports that approximately 5% of Americans (over 15 million people) have allergic symptoms from exposure to mold.  Exposure is generally unavoidable as mold and mold spores are found in almost every moist environment & thrive in a wide range of temperature and humidity.   Typical indoor molds in North America are the Penicillium and Aspergillus species, while prevalent outdoor mold species areCladosporium and Alternaria.  Pharmacotherapy (e.g. oral or nasal anti-histamines, nasal decongestants) is used to palliate the symptoms of mold allergies but does not offer a cure.  Immunotherapy to treat mold allergies offers significant advantages versus pharmacotherapy because it can ameliorate the underlying pathophysiology of the allergy in a near-permanent manner.

VLNB seeks to partner with companies and research organizations to accelerate commercial development of immunotherapy to treat mold allergies.  VLNB also offers customized consulting services led by Dr. Hari Vijay.

About VLN Biotechnology

VLN Biotechnology is commercializing immunotherapy technology to improve the health and quality of life of patients suffering from allergies to mold.  We are focused on improved detection of allergenic proteins responsible for allergic reactions and development of immunotherapy to alleviate symptoms of mold allergies.  VLN Biotechnology was founded by Dr. Hari Vijay, an acknowledged global expert on mold allergens.  For further information please visit www.vln-biotech.com.

Contact
VLN Biotechnology
(613) 355-1012
info@vln-biotechnology.com


Date: 2018-12-03